MIRA Pharmaceuticals (NASDAQ: MIRA) announced completion of dosing in its Phase 1 clinical trial for Ketamir-2, an oral drug designed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE